Under the collaboration, Panaxium’s ultra-flexible iontronic electrocorticography (ECoG) platform will be integrated into Synaptive Medical’s Modus V robotic exoscope technology.
This will provide unparalleled real-time intelligence regarding the decisive functional mapping data as well as bioelectrical connections in the human brain during surgery.
The new integration will help to protect key brain tissues during resection. It will also reduce the time taken for procedures and improve post-surgery outcomes for many life-threatening brain disorders.
Synaptive Medical president and co-founder Cameron Piron said: “Synaptive is proud to launch this research effort with extraordinary clinical partners advancing state-of-the-art in neurology and neurosurgery at renowned centres worldwide.
“Synaptive already provides automated tractography segmentation for surgical planning with our imaging system, so the integration of Panaxium’s electrocorticography into Modus V is a natural next step for our technology and an exciting leap forward in the neurosurgical space.”
The company stated that the partnership’s benefits will be demonstrated in a pilot trial, which will be conducted at hospitals in Paris, France.
The French National Institute of Health and Medical Research, INSERM, will provide funding for the trial, which will be led by Hôpital Fondation Adolphe de Rothschild and INSERM neurologist and researcher Dr Gilles Huberfeld.
Panaxium co-founder and chief product officer Dr Pierre Leleux said: “This tool provides a level of electrophysiology information that has never been accessible during procedures before.
“The extraordinary and unprecedented data we are collecting then enables software intelligence for an expanding range of procedures that would benefit from cortical mapping, including neuropsychiatric, neuro-oncology and neurodegenerative.”